Virtual Library

Start Your Search

X. Wang



Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P043 - Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer (ID 35)

      00:00 - 00:00  |  Author(s): X. Wang

      • Abstract

      Background:
      Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is clinically effective as a first-line and second-line therapy in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Use of this treatment is limited by high costs. Here, we conducted a cost-effectiveness analysis of different sequences of osimertinib administration in China and the United States.


      Method:
      We established Markov models based on data from the FLAURA and AURA3 trials, which included patients with EGFR mutation-positive advanced NSCLC. The cost-effectiveness analysis compared first-line osimertinib to first-generation EGFR-TKIs or second-line osimertinib after the failure of first-generation EGFR-TKIs. The analysis also considered different payment modalities available in China. Additionally, we performed 1-way sensitivity and probability sensitivity analyses with a willingness-to-pay threshold (WTP) of 3